SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories - Quaterly Results

27 May 2022 Evaluate
The company witnessed a 12.25% growth in the revenue at Rs. 11684.50 millions for the quarter ended March 2022 as compared to Rs. 10409.20 millions during the year-ago period.The Net Profit of the company registered a slight decline of -27.11% to Rs. 1104.10  millions from Rs. 1514.80 millions.The company reported a degrowth in operating Profit to 1932.30 millions from 2365.50 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 11684.50 10409.20 12.25 53993.60 51391.60 5.06 53993.60 51391.60 5.06
Other Income 142.10 199.10 -28.63 561.30 622.40 -9.82 561.30 622.40 -9.82
PBIDT 1932.30 2365.50 -18.31 12996.70 15758.20 -17.52 12996.70 15758.20 -17.52
Interest 32.10 23.10 38.96 72.10 81.40 -11.43 72.10 81.40 -11.43
PBDT 1900.20 2342.40 -18.88 12924.60 15676.80 -17.56 12924.60 15676.80 -17.56
Depreciation 523.90 485.70 7.86 2041.00 1877.20 8.73 2041.00 1877.20 8.73
PBT 1376.30 1856.70 -25.87 10883.60 13799.60 -21.13 10883.60 13799.60 -21.13
TAX 272.20 341.90 -20.39 2174.20 2391.90 -9.10 2174.20 2391.90 -9.10
Deferred Tax -37.60 -20.90 79.90 201.40 -57.90 -447.84 201.40 -57.90 -447.84
PAT 1104.10 1514.80 -27.11 8709.40 11407.70 -23.65 8709.40 11407.70 -23.65
Equity 253.70 253.70 0.00 253.70 253.70 0.00 253.70 253.70 0.00
PBIDTM(%) 16.54 22.73 -27.23 24.07 30.66 -21.50 24.07 30.66 -21.50

Ipca Laboratories Share Price

1557.90 -5.80 (-0.37%)
07-May-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1831.30
Dr. Reddys Lab 1307.00
Cipla 1361.00
Zydus Lifesciences 940.10
Lupin 2460.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×